Transitioning from Compounded to Brand-Name GLP-1 Medications
On April 30, 2026, the FDA proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list. This wasn’t a sudden move. Novo Nordisk and Eli Lilly had already begun legal action against major 503B facilities months earlier, and most stopped producing GLP-1s well before the FDA announcement. The writing was on the wall — the FDA simply confirmed the direction.
Three separate actions with different implications:
- 503B bulks list removal (proposed, not final): Would end large-scale production by outsourcing facilities.
- 503A tightening: FDA also narrowed conditions for state-licensed pharmacies. Importantly, 503A pharmacies operate without FDA registration, don’t disclose where they source their active ingredient, and aren’t subject to routine FDA inspection. We advise against using 503A-compounded GLP-1s.
- Shortage flex expired: Semaglutide off the FDA shortage list since February 2025, tirzepatide since December 2024. The temporary compounding permission is gone.
The Supply Situation Right Now
Most 503B facilities stopped producing GLP-1s months ago under legal pressure from Novo Nordisk and Eli Lilly. Whatever stock remains — at the wholesaler, your pharmacy, your refrigerator — is what’s left. Expect it to run out within two months, possibly sooner.
503A pharmacies are still technically operating, but we don’t recommend waiting on them. Beyond the regulatory gaps, many compounded GLP-1s on the market aren’t even FDA-approved molecules. Retatrutide, for instance, is only authorized for use in clinical studies — yet it’s being sold as “research grade” with “not for human use” labels. That’s not a product anyone should be injecting.
If you’re on a compounded GLP-1, plan your transition now.
What Patients Ask — And the Straight Answers
“Will I gain weight switching to brand?”
Same molecule, same mechanism. A patient well-controlled on compounded semaglutide transitioning to Wegovy or Ozempic, or compounded tirzepatide to Zepbound, should expect to stay well-controlled. The risk comes from a gap in therapy or landing at a lower branded dose than you were effectively on. Both are preventable with planning.
“Will my dose change?”
Probably temporarily. Compounded dosing has been more flexible than FDA-approved schedules — many patients titrated faster or landed at doses that don’t map cleanly to a branded pen. When you move to a brand product, you’ll generally step back into the FDA titration schedule and re-titrate up over 8–16 weeks. It’s worth it for safety and tolerability.
“What do I do?”
- Find out who is filling your prescription — 503B, 503A, or another source.
- Ask your doctor about brand-name options. Supply is stable.
- Plan the overlap — avoid any gap between last compounded dose and first branded dose.
The Branded Options
Semaglutide (Wegovy, Ozempic, Wegovy pill): Wegovy is FDA-approved for chronic weight management — 0.25 mg to 2.4 mg weekly as an injectable, plus a 7.2 mg high-dose option producing approximately 20% average weight loss. The Wegovy pill (oral formulation, 1.5 mg to 25 mg daily) offers a needle-free alternative. Ozempic is FDA-approved for type 2 diabetes and used off-label for weight management at similar doses.
Tirzepatide (Zepbound, Mounjaro): Zepbound is FDA-approved for chronic weight management — 2.5 to 15 mg weekly. The SURMOUNT trials showed 18–22% average weight loss at highest doses, the largest effect size of any obesity medication currently available. Mounjaro is the same molecule FDA-approved for type 2 diabetes.
Can I move from compounded semaglutide to the Wegovy pill? Yes. If you’ve been on compounded semaglutide and want to switch to the oral Wegovy pill, your prescriber can guide the transition. Dosing equivalents differ between oral and injectable formulations, so the switch should be managed with medical oversight.
Dose Mapping
Within the same molecule — compounded semaglutide to Wegovy or Ozempic, compounded tirzepatide to Zepbound or Mounjaro — the dose generally maps directly. Switching between molecules requires starting at the lowest dose of the new drug and titrating up under medical supervision.
Transition Timeline
Weeks 1–2: Choose your branded product with your prescriber. Weeks 2–4: Secure prior authorization and routing — this can take 7–14 days, so start now. Weeks 4–6: Begin the branded medication while finishing remaining compounded supply — no washout needed. Weeks 8–16: Retitrate to your therapeutic dose.
What About Cost — and Insurance?
Many patients on compounded GLP-1s from med spas or online-only outfits don’t realize they may have insurance coverage for brand-name medications. These providers typically don’t check insurance eligibility and only offer compounded products. If you’ve been paying out-of-pocket for compounded, call your insurer or ask us to check — you may have coverage you haven’t used.
We’ve helped hundreds of patients run the prior authorization process. Commercial insurance increasingly covers Wegovy or Zepbound for obesity, particularly with common comorbidities. For Medicare Part D patients, transition options have expanded. In many cases, the PA process brings out-of-pocket cost to $50/month or less — less than many patients were paying for compounded. Our Medicare GLP-1 Bridge page walks through what coverage is available and what the cost realistically looks like.
Manufacturer savings cards from Novo Nordisk and Eli Lilly can further reduce copays to as low as $25/month for eligible commercially insured patients. We’ve done this work before — we know which programs apply, which insurers move faster, and how to make the PA process as smooth as possible.
What We’ve Seen in Practice
We’ve already transitioned most of our patients from compounded to brand-name medications. The process works, and for many patients, branded options end up costing less than compounded did — once savings cards and prior authorizations are in place. We’ve done this hundreds of times and we know how to run it efficiently.
The Bottom Line
The medication that worked for you will keep working. Same molecule, same outcome — just from a different pharmacy with a different label, and for most patients, at a lower out-of-pocket cost than compounding. Two months is enough time to make the switch without losing ground.
Existing patients: call us at (303) 750-9454 to schedule a transition visit. New patients: request a consultation here.
About the Author
Dr. Ethan Lazarus, MD, FOMA
Fellow of the Obesity Medicine Association
Clinical Nutrition Center
5995 Greenwood Plaza Blvd, Suite 150
Greenwood Village, CO 80111
(303) 750-9454
clinicalnutritioncenter.com
